PHARMACOKINETIC AND PHARMACODYNAMIC OPTIMIZATION OF H. PYLORI ERADICATION THERAPY IN PATIENTS WITH ANTIBIOTIC-RESISTANT H. PYLORI INFECTION

Authors

Keywords:

Helicobacter pylori; antimicrobial resistance; pharmacokinetics; pharmacodynamics; acid suppression; amoxicillin; proton pump inhibitors; potassium-competitive acid blockers; eradication therapy; antimicrobial susceptibility.

Abstract

 Helicobacter pylori infection remains one of the most important chronic bacterial infections worldwide and is strongly associated with chronic gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. The effectiveness of eradication therapy has progressively been challenged by increasing antimicrobial resistance, particularly to clarithromycin, metronidazole, and fluoroquinolones. Consequently, treatment optimization requires not only appropriate antimicrobial selection but also a better understanding of pharmacokinetic (PK) and pharmacodynamic (PD) principles.

Pharmacokinetic factors determine drug exposure at the relevant biological site and include absorption, distribution, metabolism, and elimination. In H. pylori infection, however, systemic exposure alone does not fully predict therapeutic success. Intrabal gastric exposure, gastric pH, drug stability in the acidic environment, penetration into gastric mucus, bacterial susceptibility, and the duration of exposure are also important. Pharmacodynamic principles describe the relationship between drug exposure and antimicrobial effect. Amoxicillin is traditionally considered a time-dependent antimicrobial, making sustained exposure particularly important, whereas other agents used against H. pylori may demonstrate different exposure-response relationships. Acid suppression is also pharmacodynamically important because elevation of intragastric pH can alter bacterial physiology and improve the activity of several antimicrobial agents.

The pharmacology of acid-suppressive therapy is particularly relevant. Proton pump inhibitors are affected by CYP2C19-mediated metabolism, resulting in clinically relevant interindividual variation in acid suppression. Potassium-competitive acid blockers provide a different pharmacological approach and can achieve strong and sustained acid suppression, potentially improving the pharmacodynamic environment for antimicrobial therapy. Current international guidelines emphasize the importance of local resistance patterns, previous antibiotic exposure, susceptibility-guided treatment when available, adherence, adequate treatment duration, and confirmation of eradication. A pharmacokinetic/pharmacodynamic framework therefore provides a rational basis for understanding treatment failure and for developing more effective strategies against antibiotic-resistant H. pylori.

 

References

1.Ashurova NG, Tolibov FF. Impact of stress on female reproductive health: disorders and implications. Journal of Education and Scientific Medicine. 2025;5.

2.Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, Shah SC. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2024;119(9):1730–1753. doi:10.14309/ajg.0000000000002968.

3.Farxodivich TF. Cholestasis is a risk factor for the development of gallstone disease. Nauchnyi Fokus. 2024;2(21):317–321.

4.Farxodivich TF. Clinical characteristics of gastritis in digestive diseases. Research Journal of Trauma and Disability Studies. 2024;3(3):294–299.

5.Farxodivich TF. Infection of COVID-19 on cognitive functions. Scientific Journal of Applied and Medical Sciences. 2024;3(4):325–330.

6.Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastrointest Clin North Am. 2010. doi:10.1016/j.gtc.2010.08.007.

7.Hu Y, Huang XH, Zhou B, et al. Vonoprazan and amoxicillin dual therapy for 14 days as the first-line treatment of Helicobacter pylori infection: a non-inferiority, randomized clinical trial. Helicobacter. 2024;29(1). doi:10.1111/hel.13045.

8.Ishizaki T, Horai Y. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opin Drug Metab Toxicol. 2009. doi:10.1517/17425250903386251.

9.Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence Consensus Report. Gut. 2022;71(9):1724–1762. doi:10.1136/gutjnl-2022-327745.

10.Peng X, Yao JY, Ma YQ, et al. Efficacy and safety of vonoprazan-amoxicillin dual regimen with varying dose and duration for Helicobacter pylori eradication. Clin Gastroenterol Hepatol. 2024;22(6):1210–1216. doi:10.1016/j.cgh.2024.01.022.

11.Qiu S, Huang Y, Chen J, et al. Vonoprazan-amoxicillin dual therapy with different amoxicillin administration regimens for Helicobacter pylori treatment: a randomized controlled trial. Helicobacter. 2024. doi:10.1111/hel.13118.

12.Ru S, Jiang F, et al. Global primary antibiotic resistance rate of Helicobacter pylori in recent 10 years: a systematic review and meta-analysis. Helicobacter. 2024. doi:10.1111/hel.13103.

13.Tolibov FF. Immune system: anatomy of the lymphatic system and mechanisms of immune response. Zhurnal akademicheskikh issledovaniy novogo Uzbekistana. 2024;1(2):55–58. doi:10.5281/zenodo.10688710.

14.Tolibov FF. Clinical and morphological correlations of liver cirrhosis. Eur J Mod Med Pract. 2024;4(11):515–520.

15.Tolibov FF. Extra-articular manifestations of rheumatoid arthritis. Modern Science and Research. 2025;4(5):1080–1087.

16.Tolibov FF. Impact of corticosteroid and immunosuppressive therapy on the course of chronic hepatitis: risks and prospects. Modern Science and Research. 2025;4(2):1123–1132.

17.Tolibov FF. Mononuclear cell infiltration accompanied by the progression of fibrotic and cirrhotic transformations in the liver tissue. Modern Science and Research. 2025;4(4):926–936. doi:10.5281/zenodo.15227499.

18.Tolibov FF. Pathomorphological abnormalities of the liver in patients infected with the hepatitis B virus. Modern Science and Research. 2025;4(3):1084–1093.

19.Tolibov FF. Violation of platelet aggregation and imbalance of hemostasis in patients with chronic viral hepatitis C. New Day in Medicine. 2024;6(68):264–268. Available from: https://newdayworldmedicine.com/en/article/3758

20.Tolibov FF. The syndrome of external secretory function insufficiency is a common complication of chronic pancreatitis. American Journal of Bioscience and Clinical Integrity. 2024;1(10):90–95.

21.Tolibov FF, Shuhrat o'g'li RK. Diabetik nevropatiya va uning zamonaviy terapiyasi. Journal of Innovations in Scientific and Educational Research. 2025;8(1):195–202.

22.Influence of cytochrome P450 2C19 genotype on Helicobacter pylori proton pump inhibitor-amoxicillin-clarithromycin eradication therapy: a meta-analysis. Front Pharmacol. 2021. doi:10.3389/fphar.2021.759249.

Published

2026-09-19